2013 ACCFAHA Guideline for the Management of Heart

Applying Classification of Recommendation and Level of Evidence Copyright © American Heart Association, Inc.

Biomarkers in HF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Noninvasive Cardiac Imaging Yancy C et al. Circulation 2013; 128: e 240 -e 327

Invasive Evaluation Yancy C et al. Circulation 2013; 128: e 240 -e 327

Treatment of Stage B HF Yancy C et al. Circulation 2013; 128: e 240

Stage C HFr. EF: evidence-based, guideline-directed medical therapy Yancy C et al. Circulation 2013;

Recommendations for Pharmacological Therapy for Management of Stage C HFr. EF Yancy C et

Recommendations for Treatment of HFp. EF Yancy C et al. Circulation 2013; 128: e

Recommendations for Device Therapy for Management of Stage C HF Yancy C et al.

Indications for CRT therapy algorithm Yancy C et al. Circulation 2013; 128: e 240

Recommendations for Inotropic Support, MCS, and Cardiac Transplantation EF<25%, NYHA III-IV. Yancy C et

Stages in the development of HF and recommended therapy by stage Yancy C et

Classification of patients presenting with acutely decompensated heart failure Yancy C et al. Circulation

Recommendations for Therapies in the Hospitalized HF Patient Yancy C et al. Circulation 2013;

Recommendations for Hospital Discharge Yancy C et al. Circulation 2013; 128: e 240 -e

Pharmacological management of patients with newly discovered AF (atrial fibrillation) and HF Yancy C

Pharmacological management of patients with recurrent paroxysmal AF Yancy C et al. Circulation 2013;

Surgical/Percutaneous/Transcatheter Interventional Treatments of HF Yancy C et al. Circulation 2013; 128: e 240

Slides: 19

Download presentation

2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy et al. Circulation, Volume 128(16): e 240 -e 327, October 15, 2013 Copyright © American Heart Association, Inc. All rights reserved.

Biomarkers in HF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Noninvasive Cardiac Imaging Yancy C et al. Circulation 2013; 128: e 240 -e 327

Invasive Evaluation Yancy C et al. Circulation 2013; 128: e 240 -e 327

Treatment of Stage B HF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Stage C HFr. EF: evidence-based, guideline-directed medical therapy Yancy C et al. Circulation 2013; 128: e 240 -e 327

Recommendations for Pharmacological Therapy for Management of Stage C HFr. EF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Recommendations for Treatment of HFp. EF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Recommendations for Device Therapy for Management of Stage C HF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Indications for CRT therapy algorithm Yancy C et al. Circulation 2013; 128: e 240 -e 327

Recommendations for Inotropic Support, MCS, and Cardiac Transplantation EF<25%, NYHA III-IV. Yancy C et al. Circulation 2013; 128: e 240 -e 327

Stages in the development of HF and recommended therapy by stage Yancy C et al. Circulation 2013; 128: e 240 -e 327

Classification of patients presenting with acutely decompensated heart failure Yancy C et al. Circulation 2013; 128: e 240 -e 327

Recommendations for Therapies in the Hospitalized HF Patient Yancy C et al. Circulation 2013; 128: e 240 -e 327

Recommendations for Hospital Discharge Yancy C et al. Circulation 2013; 128: e 240 -e 327

Pharmacological management of patients with newly discovered AF (atrial fibrillation) and HF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Pharmacological management of patients with recurrent paroxysmal AF Yancy C et al. Circulation 2013; 128: e 240 -e 327

Surgical/Percutaneous/Transcatheter Interventional Treatments of HF Yancy C et al. Circulation 2013; 128: e 240 -e 327